Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 IND application has been approved by FDA in Sept, 2016 and further by TFDA in Jan, 2017.

T-1101 acts through disrupting the interaction between Hec1 and Nek2, these proteins involved in mitotic regulation that are highly expressed in cancer cells. This disruption leads to chromosomal misalignment during metaphase and triggers a series of downstream events that result in induction of apoptosis. 

T-1101 demonstrated potent anti-cancer activity across numerous human cancer cell lines and also showed tumor growth inhibition in different mouse xenograft models of human cancers, including liver and triple negative breast cancer.

Taivex has granted the exclusive rights in every step in new drug development of the small molecule T-1101 with global patents.